Answers are grounded in this paper and cite their sources.
OBJECTIVES: To evaluate temporal trends in anticoagulant (AC) and antiplatelet (AP) use among patients undergoing operative treatment of hip fractures and to assess the association of antithrombotic regimen with time to surgery and postoperative outcomes. METHODS: Design: Retrospective cohort study. SETTING: Single North American Level I trauma center. PATIENT SELECTION CRITERIA: Patients aged 55 years or older who underwent operative treatment for a hip fracture (AO/OTA types 31-A, 31-B, and 31-C) between 2000 and 2022 while receiving anticoagulant and/or antiplatelet therapy at admission were included. OUTCOME MEASURES AND COMPARISONS: Temporal trends in antithrombotic prescribing, time to surgery, perioperative transfusion, readmission, 90-day medical and surgical postoperative complications, and 90-day mortality were assessed. The odds of warfarin versus direct oral anticoagulant (DOAC) prescription were compared across study years, and time to surgery from admission and each outcome were compared across study years and across antithrombotic regimens (warfarin, DOAC, DOAC or warfarin plus antiplatelet, and antiplatelet alone). RESULTS: 476 patients were included (mean age 81.2 years [range, 60-103]; 288 [60.4%] female). Anticoagulant therapy was used by 155 (32.7%) and antiplatelet therapy by 385 (80.7%); 64 (13.4%) received both. The odds of warfarin prescription relative to a DOAC decreased by an estimated 37% per year (odds ratio [OR] 0.63, 95% CI 0.53-0.74; P<0.001). Time to surgery did not change significantly over the study period (-0.01 hours/year, 95% CI -0.04 to 0.02; P=0.4) and was not associated with antithrombotic regimen (-0.01, 95% CI: -0.04-0.01; P=0.3). Perioperative transfusion odds decreased 12% per year (OR 0.88, 95% CI 0.84-0.93; P<0.001) and 1-year readmission odds decreased 46% per year (OR 0.54, 95% CI 0.48-0.60; P<0.001), independent of medication class. Ninety-day (OR 0.99, 95% CI 0.95-1.04; P=0.8) and 90-day mortality (OR 0.79, 95% CI 0.54-1.14; P=0.2) did not change over time. CONCLUSIONS: In this 22-year single-center cohort of hip-fracture patients receiving anticoagulant (AC) or antiplatelet (AP) therapy, antithrombotic regimen was not associated with time to surgery, 90-day complications, or mortality. Perioperative transfusion and 1-year readmission rates declined over the study period independent of medication class. These findings supported expedited operative management of hip fractures in patients receiving AC or AP therapy. LEVEL OF EVIDENCE: III.
No takes yet. Share an insight, caveat, or question.
House et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: